
|Videos|November 4, 2015
How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?
Author(s)Davy James, Managing Editor
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Advertisement
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Common Virus May Hold New Clues to Lupus
2
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
3
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
4
Managing Safety and Supportive Care With Pluvicto: Insights From the PSMAddition Trial
5
















































































































































































































